Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
April 01, 2021 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2021 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
February 24, 2021 16:01 ET
|
Paratek Pharmaceuticals
-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020-- NUZYRA Expansion into the Primary Care Setting in 2021 -- Paratek Expects...
Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
February 17, 2021 16:01 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Expansion of NUZYRA® Launch into the Community Setting
February 08, 2021 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a biopharmaceutical company that develops and commercializes life-saving therapies for public health threats...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
February 01, 2021 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
January 06, 2021 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group
January 04, 2021 17:00 ET
|
Paratek Pharmaceuticals
BOSTON, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 01, 2020 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...